Genmab — Oktober 2022
-
Oxford BioTherapeutics enters into Commercial License Agreement with Genmab https://www.prnewswire.com/news-releases/oxford-biotherapeutics-enters-into-commercial-license-agreement-with-genmab-301638067.html
-
Hvorfor egenligt det?
-
Det er vi enige om gdn55.
-
Der var faktisk en lille nyhed i eftermiddags: Oxford, UK and San Jose, California, 3 October 2022 - Oxford BioTherapeutics (OBT), a clinical
stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate
(ADC)-based therapies, today announced that global oncology leader, Genmab has licensed a
novel antibody related to one of OBT’s IO programs. -
Godmorgen.
-
Gentogen.. Vi havde den her,
Genmab indgår aftale om kommercialisering af antistof fra Oxford Bio https://www.proinvestor.com/investornyt/885745/genmab-indgar-aftale-om-kommercialisering-af-antistof-fra-oxford-bio -
Normalt ikke noget som er kursdrivende.
-
Godmorgen
-
Tirsdagens aviser med Novo Nordisk, Schouw og Arla https://www.proinvestor.com/investornyt/886057/tirsdagens-aviser-med-novo-nordisk-schouw-og-arla
-
Aktier/tendens: Sønderslåede aktier får opmærksomhed før grøn start https://www.proinvestor.com/investornyt/886074/aktier-tendens-sonderslaede-aktier-far-opmaerksomhed-for-gron-start
-
small new Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia https://clinicaltrials.gov/ct2/show/NCT05562882
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind